country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P99100A

Copy Link Print Information

Visugromab (Powder)

Name: Visugromab (Powder)
Brand: MedChemExpress
SKU: HY-P99100A
Availability: PreOrder

(Synonyms: CLT-002 (Powder))

2 Cited Publications

Avis client

Based on 2 publication(s) in Google Scholar

Visugromab (CTL-002) (Powder) is a GDF-15 neutralizing IgG4 mAb. Visugromab (Powder) has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No.: 2556646-63-8

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (258 KB)

Visugromab (Powder) Chemical Structure

CAS No.: 2556646-63-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- In Vivo
- Conjugated
- Reconsititution
- Format
- Application
Chemical Information
Publications (2)
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

GDF15

Voir tous les produits spécifiques à Isoform TGF-beta/Smad :

Smad1
Smad3

Voir tous les produits spécifiques à Isoform TGF-β Receptor :

In Vivo

Visugromab (up to 100 mg/kg; per week) shows no toxicity in the pre-clinical toxicology test of cynomolgus monkeys^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

IgG4-kappa

Application

ELISA, FACS, Functional assay

Chemical Information

CAS No. 2556646-63-8
SMILES

[Visugromab (Powder)]
Synonyms

CLT-002 (Powder)
Formulation

Please refer to the lot-specific COA for specific buffer information.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (2)

All ELISACell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Mol Cell Biochem

Senescence of endothelial cells promotes phenotypic changes in adventitial fibroblasts: possible implications for vascular aging. [Abstract]

2025 Feb;480(2):1027-1043. PMID: 38743322

Visugromab (Powder) purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2025 Feb;480(2):1027-1043. [Abstract]

GDF-15 protein level measured by ELISA in CM following 1h incubation with different concentrations of Visugromab (0.625-20 μg/mL). 20 μg/mL was selected as the effective neutralization concentration.

Visugromab (Powder) purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2025 Feb;480(2):1027-1043. [Abstract]

The quantification of EdU positive nuclei as a percentage of all nuclei for hAdv cultured in control conditions (hAdv) or in the presence of Visugromab (20 μg/ml) in culture medium. Addition of Visugromab directly to hAdv cells culture medium resulted in decreased proliferation rate of the cells.
bioRxiv

2025 Oct 23.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (258 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Références

[1]. Necchi A, et al. Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC): A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (NEO-GDFATHER)[J]. 2023.

[2]. Melero I, et al. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 Jan;637(8048):1218-1227. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

Visugromab (Powder)

2 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis

Amount: USD 0.00

Activité biologique
- Description
- IC₅₀ & Target
- In Vivo
- Conjugated
- Reconsititution
- Format
- Application
Chemical Information
Publications (2)
Pureté et documentation
Références

1/16

IgG4-kappa
1/16

Visugromab (Powder) purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2025 Feb;480(2):1027-1043. [Abstract]

Customer Validation
GDF-15 protein level measured by ELISA in CM following 1h incubation with different concentrations of Visugromab (0.625-20 μg/mL). 20 μg/mL was selected as the effective neutralization concentration.
1/16

Visugromab (Powder) purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2025 Feb;480(2):1027-1043. [Abstract]

Customer Validation
The quantification of EdU positive nuclei as a percentage of all nuclei for hAdv cultured in control conditions (hAdv) or in the presence of Visugromab (20 μg/ml) in culture medium. Addition of Visugromab directly to hAdv cells culture medium resulted in decreased proliferation rate of the cells.
1/16

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Visugromab (Powder)

Publications Citing Use of MedChemExpress (MCE) Visugromab (Powder)

Voir tous les produits spécifiques à Isoform TGF-beta/Smad

Voir tous les produits spécifiques à Isoform TGF-β Receptor

Activité biologique

Chemical Information

Publications (2)

Pureté et documentation

Références

Calculators

Help & FAQs

Visugromab (Powder) Related Classifications

HY-P99100A Related Classifications

Bioz